Drugs / very small embryonic-like stem cell
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03976206 | Jul 2019 → May 2020 | dermatitis, disease related to hematopoietic stem cell transplant | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03975101 | Jul 2019 → May 2020 | disease related to hematopoietic stem cell transplant, osteoarthritis, knee | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03985462 | Jul 2019 → May 2020 | disease related to hematopoietic stem cell transplant, primary ovarian failure | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | very small embryonic-like stem cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03985462 ↗ |
| Known as | VSEL | “The aim of this study is the safety and efficacy of autologous very small embryonic-like stem cells(VSELs) to facial skin antiaging.” NCT03976206 ↗ |
| Modality | Cell therapy | “very small embryonic-like stem cell” NCT03975101 ↗ |
| Route | Other | “injected into the selected knee of the patient” NCT03975101 ↗ |